Compare · ACXP vs JNJ
ACXP vs JNJ
Side-by-side comparison of Acurx Pharmaceuticals Inc. (ACXP) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACXP and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $452.25B, about 11409.8x ACXP ($39.6M).
- Over the past year, ACXP is down 75.9% and JNJ is up 46.5% - JNJ leads by 122.4 points.
- Both names hit the wire about 13 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 1 for ACXP).
- Company
- Acurx Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $1.99+0.00%
- $227.47-1.37%
- Market cap
- $39.6M
- $452.25B
- 1M return
- -53.12%
- -5.19%
- 1Y return
- -75.87%
- +46.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 13
- 13
- Recent ratings
- 1
- 25
Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ACXP
- SEC Form 4 filed by Sailer Carl
- SEC Form 4 filed by Dean Jack H
- SEC Form 4 filed by Donohue James J.
- SEC Form 4 filed by Harrison Thomas L
- SEC Form 4 filed by Scodari Joseph C
- SEC Form 4 filed by Deluccia Robert J
- SEC Form 4 filed by Luci David P
- SEC Form 4 filed by Shawah Robert G.
- Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
- Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision